GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Analysts have a consensus "Hold" rating on GoodRx from 15 analysts (3 sell, 7 hold, 5 buy) with an average 1‑year target of $3.85, and several firms recently cut price targets to roughly $3.00–$3.50.
• GoodRx reported Q results of $0.09 EPS (in line) and $194.79M revenue (slightly above estimates) but revenue was down 1.9% year‑over‑year; shares trade near $2.56 with a market cap of about $877M and a 12‑month range of $1.77–$5.81.

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have earned a consensus recommendation of "Hold" from the fifteen analysts that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $3.8542.

A number of equities analysts have recently issued reports on the stock. Mizuho cut their price objective on shares of GoodRx from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Friday, February 27th. JPMorgan Chase & Co. reissued a "neutral" rating on shares of GoodRx in a research report on Friday, February 27th. Leerink Partners reissued an "outperform" rating and set a $3.00 price objective on shares of GoodRx in a research report on Thursday, February 26th. Wells Fargo & Company cut their price objective on shares of GoodRx from $7.00 to $3.50 and set an "overweight" rating on the stock in a research report on Wednesday, March 4th. Finally, Citigroup cut their price objective on shares of GoodRx from $4.50 to $3.50 and set a "buy" rating on the stock in a research report on Tuesday, March 3rd.

Hedge Funds Weigh In On GoodRx

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP bought a new position in shares of GoodRx during the 3rd quarter worth about $33,000. Cetera Investment Advisers acquired a new stake in shares of GoodRx in the 2nd quarter worth about $50,000. Boothbay Fund Management LLC acquired a new stake in shares of GoodRx in the 3rd quarter worth about $43,000. Meridian Wealth Management LLC acquired a new stake in shares of GoodRx in the 4th quarter worth about $29,000. Finally, Shay Capital LLC acquired a new stake in shares of GoodRx in the 3rd quarter worth about $47,000. Institutional investors own 63.77% of the company's stock.

GoodRx Stock Performance

Shares of GDRX opened at $2.56 on Wednesday. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $876.98 million, a P/E ratio of 28.45, a price-to-earnings-growth ratio of 1.73 and a beta of 1.54. The firm's fifty day simple moving average is $2.19 and its two-hundred day simple moving average is $2.60. GoodRx has a 12 month low of $1.77 and a 12 month high of $5.81.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.09 EPS for the quarter, meeting analysts' consensus estimates of $0.09. The business had revenue of $194.79 million for the quarter, compared to analysts' expectations of $193.27 million. GoodRx had a net margin of 3.82% and a return on equity of 9.31%. The business's quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.09 earnings per share. As a group, analysts predict that GoodRx will post 0.15 EPS for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.